Oculis to go Public via EBAC SPAC Merger for ~$220M
- The combined company is expected to have a post-transaction enterprise value of ~$220M with a cash balance of ~$200M incl. ~$127.5M in EBAC’s trust & $80M upsized PIPE and private investment with the participation of institutional investors. The transaction is expected to be close in H1’23
- The combined company will be named “Oculis Holding SA”. Oculis advances its diversified product portfolio incl. OCS-01, currently in the P-III trial for retina, P-IIb trials of OCS-02 for DED & uveitis, and a PoC trial of OCS-05 for acute optic neuritis
- Oculis has already been involved in multiple preclinical development activities incl. OCS-03 for corneal neovascularization & is also evaluating the preclinical candidate OCS-04 for use in corneal transplant
Ref: Globenewswire | Image: Oculis
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.